Alexion shares rise after report of approach by Roche
July 30 (Reuters) - Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.
Bloomberg, citing one unnamed person with knowledge of the matter, said that Alexion had rebuffed the approach and had retained Goldman Sachs to prepare for a possible offer.
Officials at Alexion and Roche were not immediately available to comment on the report. Goldman Sachs declined to comment.
Earlier this month, people familiar with the matter told Reuters that Roche was seeking financing for a potential bid for Alexion, whose market value neared $22 billion before Tuesday's share move.
Alexion sells Soliris, one of the world's most expensive medicines, used to treat a progressive, life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria that causes destruction of red blood cells. (Reporting by Bill Berkrot; Editing by Carol Bishopric)
- Merkel says tightening Ukraine-Russian border is key to peace deal |
- China rejects U.S. criticism over jet encounter
- Protesters mark two weeks since police shooting in Ferguson, Missouri |
- U.S. hostage rescuers dropped from night sky: Syria activist
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |